{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:07:01Z","timestamp":1771643221811,"version":"3.50.1"},"reference-count":22,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Umbilical cord blood (UCB) is the preferred donor cell source for children with Hurler syndrome undergoing transplant, and its use has been associated with improved \u201cengrafted survival\u201d rates. However, as in other pediatric recipients of UCB transplants for nonmalignant disease, immune-mediated cytopenia (IMC) is a significant complication. This article describes 8 episodes of IMC in 36 patients with Hurler syndrome undergoing UCB transplant. The incidence of IMC was increased in those with a higher preconditioning absolute lymphocyte count and in those conditioned with fludarabine-containing regimens rather than cyclophosphamide, and it included red cell alloantibodies directed at cord blood group antigens that are novel to the recipient. In several cases, IMC was a precursor to immune-mediated complete graft rejection. We describe IMC as part of a spectrum of graft rejection by a residual competent host immune system and a forme fruste of complete graft rejection.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018026963","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T16:45:54Z","timestamp":1550681154000},"page":"570-574","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Immune cytopenia post\u2013cord transplant in Hurler syndrome is a forme fruste of graft rejection"],"prefix":"10.1182","volume":"3","author":[{"given":"David","family":"Deambrosis","sequence":"first","affiliation":[{"name":"Department of Blood and Marrow Transplant, Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Han","family":"Lum","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant, Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan M.","family":"Hum","sequence":"additional","affiliation":[{"name":"Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Poulton","sequence":"additional","affiliation":[{"name":"Transplantation Laboratory, Manchester Royal Infirmary, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Ogden","sequence":"additional","affiliation":[{"name":"Transplantation Laboratory, Manchester Royal Infirmary, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Inherited Metabolic Disease, Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Stanworth","sequence":"additional","affiliation":[{"name":"Department of Haematology, John Radcliffe Hospital, Oxford, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Bonney","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant, Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prashant","family":"Hiwarkar","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant, Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Wynn","sequence":"additional","affiliation":[{"name":"Department of Blood and Marrow Transplant, Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"2020021108340428400_B1","article-title":"The mucopolysaccharidoses","author":"Neufeld"},{"issue":"3","key":"2020021108340428400_B2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/bjh.13059","article-title":"Transplantation in inborn errors of metabolism: current considerations and future perspectives","volume":"167","author":"Boelens","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2020021108340428400_B3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"de Ru","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"24","key":"2020021108340428400_B4","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1182\/bloodadvances.2017011387","article-title":"Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation","volume":"1","author":"Aldenhoven","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"2020021108340428400_B5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jpeds.2008.11.005","article-title":"Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy","volume":"154","author":"Wynn","year":"2009","journal-title":"J Pediatr"},{"issue":"19","key":"2020021108340428400_B6","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1182\/blood-2012-09-455238","article-title":"Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning","volume":"121","author":"Boelens","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2020021108340428400_B7","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/bmt.2017.5","article-title":"Changes in the incidence, patterns and outcomes of graft failure following hematopoietic stem cell transplantation for Hurler syndrome","volume":"52","author":"Lum","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"2020021108340428400_B8","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1056\/NEJMoa032613","article-title":"Cord-blood transplants from unrelated donors in patients with Hurler\u2019s syndrome","volume":"350","author":"Staba","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"2020021108340428400_B9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.bmt.1705718","article-title":"Outcomes of hematopoietic stem cell transplantation for Hurler\u2019s syndrome in Europe: a risk factor analysis for graft failure","volume":"40","author":"Boelens","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2020021108340428400_B10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020021108340428400_B11","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2141.2009.07974.x","article-title":"Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions","volume":"148","author":"Prasad","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"2020021108340428400_B12","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2012-07-445965","article-title":"New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation","volume":"121","author":"Daikeler","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2020021108340428400_B13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbmt.2009.01.020","article-title":"Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with Hurler syndrome","volume":"15","author":"Boelens","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020021108340428400_B14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020021108340428400_B15","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/bloodadvances.2018016956","article-title":"Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine","volume":"2","author":"Harris","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2020021108340428400_B16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/blood-2013-05-502385","article-title":"Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome","volume":"123","author":"Lindemans","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2020021108340428400_B17","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","article-title":"Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation","volume":"128","author":"Admiraal","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020021108340428400_B18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10545-012-9500-3","article-title":"Management of mucopolysaccharidosis type IH (Hurler\u2019s syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution\u2019s experience","volume":"36","author":"Wiseman","year":"2013","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"2020021108340428400_B19","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1097\/MPH.0000000000000191","article-title":"Complications of Reduced Intensity Conditioning HSCT for XIAP Deficiency (Alloimmune Cytopenias and HLH) Successfully Managed With Donor Lymphocyte Infusion","volume":"37","author":"Varghese","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"2020021108340428400_B20","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"2020021108340428400_B21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbmt.2017.08.029","article-title":"Optimizing anti-thymocyte globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based on recipient absolute lymphocyte count","volume":"24","author":"Kennedy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020021108340428400_B22","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1182\/blood.V126.23.4410.4410","article-title":"Optimizing anti-thymocyte globulin dosing based on recipient absolute lymphocyte count after unrelated allogeneic hematopoietic cell transplant","volume":"126","author":"Kennedy","year":"2015","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/570\/1631115\/advances026963.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/4\/570\/1631115\/advances026963.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:03:40Z","timestamp":1581411820000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/4\/570\/246746\/Immune-cytopenia-postcord-transplant-in-Hurler"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,2,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018026963","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]}}}